These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 10580431

  • 1. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 2. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 3. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.
    Diabetes Care; 2000 Jan 01; 23(1):64-9. PubMed ID: 10857970
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun 01; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 5. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 6. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.
    Diabetes; 2002 Feb 01; 51(2):443-8. PubMed ID: 11812753
    [Abstract] [Full Text] [Related]

  • 7. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.
    Diabetes; 2000 Apr 01; 49(4):633-9. PubMed ID: 10871202
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.
    Diabetes Care; 2002 Mar 01; 25(3):542-9. PubMed ID: 11874944
    [Abstract] [Full Text] [Related]

  • 9. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
    Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT.
    Diabetes Res Clin Pract; 2002 Nov 01; 58(2):87-96. PubMed ID: 12213349
    [Abstract] [Full Text] [Related]

  • 10. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M.
    Diabetes Care; 1998 Dec 01; 21(12):2135-9. PubMed ID: 9839106
    [Abstract] [Full Text] [Related]

  • 11. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
    Strowig SM, Avilés-Santa ML, Raskin P.
    Diabetes Care; 2002 Oct 01; 25(10):1691-8. PubMed ID: 12351463
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.
    N Engl J Med; 1998 Mar 26; 338(13):867-72. PubMed ID: 9516221
    [Abstract] [Full Text] [Related]

  • 13. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
    Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM.
    Diabetes Care; 1992 Feb 26; 15(2):193-203. PubMed ID: 1547676
    [Abstract] [Full Text] [Related]

  • 14. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
    Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR.
    Diabetes; 2002 Jan 26; 51(1):30-6. PubMed ID: 11756319
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M.
    Metabolism; 2000 Sep 26; 49(9):1167-75. PubMed ID: 11016899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.